CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitor |
|
Accession: | CHEBI:76785
|
browse the term
|
Definition: | An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of any endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*). |
Synonyms: | related_synonym: | EC 3.1.26.* (endoribonucleases producing 5'-phosphomonoesters) inhibitors; EC 3.1.26.* inhibitor; EC 3.1.26.* inhibitors; endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*) inhibitor; endoribonuclease producing 5'-phosphomonoesters (EC 3.1.26.*) inhibitors; endoribonuclease producing 5'-phosphomonoesters inhibitor; endoribonuclease producing 5'-phosphomonoesters inhibitors |
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases export decreases export |
ISO |
[Estradiol results in decreased activity of ABCG2 protein] which results in increased uptake of abacavir; [isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate results in decreased activity of ABCG2 protein] which results in increased uptake of abacavir 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester inhibits the reaction [ABCG2 protein results in increased export of abacavir]; Elacridar inhibits the reaction [ABCG2 protein results in decreased export of abacavir]; Elacridar inhibits the reaction [ABCG2 protein results in increased export of abacavir]; Nelfinavir inhibits the reaction [ABCG2 protein results in increased export of abacavir]; pluronic block copolymer p85 inhibits the reaction [ABCG2 protein results in increased export of abacavir] |
CTD |
PMID:17437964 PMID:19056916 PMID:25844889 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
abacavir binds to ALB protein abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
abacavir results in decreased expression of ALDH1A2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
abacavir results in increased expression of CRP protein |
CTD |
PMID:19891054 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
abacavir results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
abacavir results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
abacavir results in decreased expression of EYA1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases expression |
ISO |
abacavir results in increased expression of FGF8 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Foxc2 |
forkhead box C2 |
decreases expression |
ISO |
abacavir results in decreased expression of FOXC2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr19:49,186,034...49,188,736
Ensembl chr19:49,185,662...49,188,737
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
ISO |
abacavir results in increased expression of GFAP protein |
CTD |
PMID:19358275 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Hoxb7 |
homeo box B7 |
increases expression |
ISO |
abacavir results in increased expression of HOXB7 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:81,252,616...81,256,034
Ensembl chr10:81,252,553...81,256,034
|
|
G |
Hoxb9 |
homeo box B9 |
increases expression |
ISO |
abacavir results in increased expression of HOXB9 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of IFNG protein |
CTD |
PMID:23541086 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of IL13 protein |
CTD |
PMID:23541086 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il4 |
interleukin 4 |
affects response to substance |
ISO |
IL4 protein affects the susceptibility to abacavir |
CTD |
PMID:15867870 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Meox1 |
mesenchyme homeobox 1 |
decreases expression |
ISO |
abacavir results in decreased expression of MEOX1 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660
|
|
G |
Mesp2 |
mesoderm posterior bHLH transcription factor 2 |
decreases expression |
ISO |
abacavir results in decreased expression of MESP2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:133,756,601...133,759,198
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
abacavir results in increased expression of MMP9 protein |
CTD |
PMID:19891054 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
increases expression |
ISO |
abacavir results in increased expression of MPO protein |
CTD |
PMID:19891054 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Neurog2 |
neurogenin 2 |
increases expression |
ISO |
abacavir results in increased expression of NEUROG2 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 2:216,092,709...216,095,276
Ensembl chr 2:216,093,363...216,094,154
|
|
G |
Olig3 |
oligodendrocyte transcription factor 3 |
increases expression |
ISO |
abacavir results in increased expression of OLIG3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 1:14,081,259...14,083,336
Ensembl chr 1:14,081,328...14,082,149
|
|
G |
Pax3 |
paired box 3 |
decreases expression |
ISO |
abacavir results in decreased expression of PAX3 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042
|
|
G |
Pax6 |
paired box 6 |
increases expression |
ISO |
abacavir results in increased expression of PAX6 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pdcd1 |
programmed cell death 1 |
multiple interactions |
ISO |
[HLA-B protein alternative form results in increased susceptibility to abacavir] which results in increased expression of PDCD1 |
CTD |
PMID:34606953 |
|
NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
[Quinine results in decreased activity of SLC22A1] which results in decreased uptake of abacavir |
CTD |
PMID:25844889 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Syp |
synaptophysin |
increases expression |
ISO |
abacavir results in increased expression of SYP protein |
CTD |
PMID:19358275 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tcf15 |
transcription factor 15 |
decreases expression |
ISO |
abacavir results in decreased expression of TCF15 mRNA |
CTD |
PMID:31711903 |
|
NCBI chr 3:140,638,984...140,644,766
Ensembl chr 3:140,638,984...140,644,766
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity |
ISO |
abacavir results in decreased activity of TERT protein |
CTD |
PMID:19358275 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[HLA-B protein polymorphism results in increased susceptibility to abacavir] which results in increased secretion of TNF protein |
CTD |
PMID:23541086 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression |
ISO |
abacavir results in increased expression of UCP1 mRNA |
CTD |
PMID:14518702 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Uncx |
UNC homeobox |
decreases expression |
ISO |
abacavir results in decreased expression of UNCX mRNA |
CTD |
PMID:31711903 |
|
NCBI chr12:15,092,779...15,097,300
Ensembl chr12:15,092,784...15,097,300
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions affects transport |
EXP |
Calcitriol promotes the reaction [ABCB4 protein affects the transport of adefovir] |
CTD |
PMID:21240898 PMID:21341280 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
affects abundance multiple interactions decreases expression increases export |
ISO EXP |
ABCC4 protein affects the abundance of adefovir [adefovir co-treated with Probenecid co-treated with Cromolyn Sodium] affects the expression of ABCC4 protein; [adefovir co-treated with Probenecid co-treated with Valsartan] affects the expression of ABCC4 protein; [adefovir co-treated with Probenecid] results in decreased expression of ABCC4 protein adefovir results in decreased expression of ABCC4 protein ABCC4 protein results in increased export of adefovir |
CTD |
PMID:18364470 PMID:35114312 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
adefovir results in increased expression of ACTA2 protein [adefovir co-treated with Probenecid] results in increased expression of ACTA2 protein; Cromolyn Sodium inhibits the reaction [[adefovir co-treated with Probenecid] results in increased expression of ACTA2 protein]; Valsartan inhibits the reaction [[adefovir co-treated with Probenecid] results in increased expression of ACTA2 protein] |
CTD |
PMID:35114312 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
[Probenecid co-treated with adefovir] results in increased expression of AGT protein; [Probenecid co-treated with Valsartan co-treated with adefovir] results in increased expression of AGT protein; Cromolyn Sodium inhibits the reaction [[Probenecid co-treated with adefovir] results in increased expression of AGT protein] |
CTD |
PMID:35114312 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
B2m |
beta-2 microglobulin |
increases secretion |
EXP |
adefovir results in increased secretion of B2M protein |
CTD |
PMID:27742868 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Calb1 |
calbindin 1 |
increases secretion |
EXP |
adefovir results in increased secretion of CALB1 protein |
CTD |
PMID:27742868 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Cma1 |
chymase 1 |
increases secretion |
EXP |
adefovir results in increased secretion of CMA1 protein |
CTD |
PMID:35114312 |
|
NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233
|
|
G |
Cst3 |
cystatin C |
multiple interactions increases expression |
EXP |
[adefovir co-treated with Probenecid] results in increased expression of CST3 protein; [Probenecid co-treated with Valsartan co-treated with adefovir] results in increased expression of CST3 protein; [Probenecid co-treated with Valsartan] inhibits the reaction [adefovir results in increased expression of CST3 protein]; Cromolyn Sodium inhibits the reaction [[adefovir co-treated with Probenecid] results in increased expression of CST3 protein] |
CTD |
PMID:35114312 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases secretion |
EXP |
adefovir results in increased secretion of HAVCR1 protein |
CTD |
PMID:27742868 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Lcn2 |
lipocalin 2 |
increases secretion |
EXP |
adefovir results in increased secretion of LCN2 protein |
CTD |
PMID:27742868 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Mmut |
methylmalonyl-CoA mutase |
affects expression increases expression |
ISO |
adefovir affects the expression of MMUT mRNA mutant form; adefovir affects the expression of MMUT protein mutant form adefovir results in increased expression of MMUT mRNA; adefovir results in increased expression of MMUT protein |
CTD |
PMID:19199343 PMID:19427250 |
|
NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
increases uptake multiple interactions decreases expression affects response to substance increases response to substance |
EXP ISO |
SLC22A6 protein results in increased uptake of adefovir [adefovir co-treated with Probenecid co-treated with Cromolyn Sodium] affects the expression of SLC22A6 protein; [adefovir co-treated with Probenecid co-treated with Valsartan] affects the expression of SLC22A6 protein; [adefovir co-treated with Probenecid] results in decreased expression of SLC22A6 protein; Valsartan inhibits the reaction [[adefovir co-treated with Probenecid] results in decreased expression of SLC22A6 protein] adefovir results in decreased expression of SLC22A6 protein SLC22A6 protein affects the susceptibility to adefovir adefovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]; Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to adefovir]; quercetin 3'-sulfate inhibits the reaction [SLC22A6 protein affects the susceptibility to adefovir]; SLC22A6 protein results in increased uptake of and results in increased susceptibility to adefovir |
CTD |
PMID:16857889 PMID:21244849 PMID:23856525 PMID:25448811 PMID:35114312 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases response to substance multiple interactions decreases expression |
ISO EXP |
SLC22A8 protein results in increased susceptibility to adefovir [adefovir co-treated with Probenecid co-treated with Cromolyn Sodium] results in increased expression of SLC22A8 protein; [adefovir co-treated with Probenecid co-treated with Valsartan] results in increased expression of SLC22A8 protein; [adefovir co-treated with Probenecid] results in decreased expression of SLC22A8 protein; Cromolyn Sodium inhibits the reaction [[adefovir co-treated with Probenecid] results in decreased expression of SLC22A8 protein] adefovir results in decreased expression of SLC22A8 protein |
CTD |
PMID:25448811 PMID:35114312 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases secretion |
EXP |
adefovir results in increased secretion of SPP1 protein |
CTD |
PMID:27742868 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
EXP |
adefovir results in increased expression of TGFB1 protein [adefovir co-treated with Probenecid] results in increased expression of TGFB1 protein; Cromolyn Sodium inhibits the reaction [[adefovir co-treated with Probenecid] results in increased expression of TGFB1 protein]; Valsartan inhibits the reaction [[adefovir co-treated with Probenecid] results in increased expression of TGFB1 protein] |
CTD |
PMID:35114312 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects activity |
ISO |
adefovir dipivoxil affects the activity of AHR protein |
CTD |
PMID:25596134 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak4 |
adenylate kinase 4 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of AK4 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of AKR1C2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of ALDH18A1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ALDH1A3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Als2cl |
ALS2 C-terminal like |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ALS2CL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:110,863,753...110,884,434
Ensembl chr 8:110,864,975...110,884,419
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of ASNS mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ATAD2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ATF3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Aurkb |
aurora kinase B |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of AURKB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of AXL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of BAX mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of BCAR3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Bend5 |
BEN domain containing 5 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of BEND5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:126,290,648...126,336,662
Ensembl chr 5:125,254,956...126,534,367
|
|
G |
Bmf |
Bcl2 modifying factor |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of BMF mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of BTG2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Ccne2 |
cyclin E2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CCNE2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CDK6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CDKN1A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cmbl |
carboxymethylenebutenolidase homolog |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CMBL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:82,569,257...82,591,007
Ensembl chr 2:82,571,888...82,591,009
|
|
G |
Coch |
cochlin |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of COCH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of CTH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of CTSC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of CYP1B1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
adefovir dipivoxil results in decreased activity of CYP3A4 protein |
CTD |
PMID:17162464 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddb2 |
damage specific DNA binding protein 2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DDB2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DGKA mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Dlgap5 |
DLG associated protein 5 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DLGAP5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dlx1 |
distal-less homeobox 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of DLX1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:56,356,190...56,360,780
Ensembl chr 3:56,356,190...56,360,780
|
|
G |
Dnai3 |
dynein axonemal intermediate chain 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DNAI3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:234,947,910...235,006,173
Ensembl chr 2:234,929,677...235,006,173
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of DPYSL3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:35,374,427...35,480,228
Ensembl chr18:35,377,181...35,480,157
|
|
G |
Efna1 |
ephrin A1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of EFNA1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ERO1A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of FAS mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fbxo22 |
F-box protein 22 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of FBXO22 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:55,579,906...55,595,981
Ensembl chr 8:55,579,891...55,596,148
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of GABARAPL1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of GADD45A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt16 |
polypeptide N-acetylgalactosaminyltransferase 16 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of GALNT16 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:100,170,306...100,250,705
|
|
G |
Gcnt3 |
glucosaminyl (N-acetyl) transferase 3, mucin type |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of GCNT3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of GDF15 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of GOT1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpr87 |
G protein-coupled receptor 87 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of GPR87 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:143,439,741...143,440,901
Ensembl chr 2:143,439,735...143,458,190
|
|
G |
H1f2 |
H1.2 linker histone, cluster member |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of H1-2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of HMOX1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of HSPA1B mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of NOS2 protein]; adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:9354585 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il19 |
interleukin 19 |
increases secretion |
ISO |
adefovir dipivoxil results in increased secretion of IL19 protein |
CTD |
PMID:24714768 |
|
NCBI chr13:42,397,715...42,411,637
Ensembl chr13:42,399,138...42,405,473
|
|
G |
Kat6b |
lysine acetyltransferase 6B |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of KAT6B mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316
|
|
G |
Kdm3a |
lysine demethylase 3A |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of KDM3A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
|
|
G |
Krt15 |
keratin 15 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of KRT15 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of LAMA3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lcn2 |
lipocalin 2 |
increases secretion |
ISO |
adefovir dipivoxil results in increased secretion of LCN2 protein |
CTD |
PMID:24714768 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of MAP3K8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of MDM2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mxi1 |
MAX interactor 1, dimerization protein |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of MXI1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:252,323,915...252,383,682
Ensembl chr 1:252,323,303...252,383,681
|
|
G |
Ncapd2 |
non-SMC condensin I complex, subunit D2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of NCAPD2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:157,968,814...157,992,314
Ensembl chr 4:157,968,815...157,992,020
|
|
G |
Ninj1 |
ninjurin 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of NINJ1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:15,452,804...15,461,684
Ensembl chr17:15,452,813...15,461,704
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of NOS2 protein]; adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; adefovir dipivoxil inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 protein] |
CTD |
PMID:9354585 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of NQO1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nrep |
neuronal regeneration related protein |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of NREP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
|
|
G |
Ntpcr |
nucleoside-triphosphatase, cancer-related |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of NTPCR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr19:53,701,496...53,715,260
Ensembl chr19:53,695,976...53,715,202
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of P4HA1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786
|
|
G |
Pank1 |
pantothenate kinase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of PANK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:232,324,718...232,395,445
Ensembl chr 1:232,328,430...232,396,829
|
|
G |
Pdia5 |
protein disulfide isomerase family A, member 5 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PDIA5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:65,272,152...65,359,087
Ensembl chr11:65,272,155...65,359,084
|
|
G |
Pdlim1 |
PDZ and LIM domain 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PDLIM1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
adefovir dipivoxil binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Phlda3 |
pleckstrin homology-like domain, family A, member 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PHLDA3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:47,193,250...47,196,335
Ensembl chr13:47,193,086...47,196,335
|
|
G |
Pidd1 |
p53-induced death domain protein 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PIDD1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699
|
|
G |
Pir |
pirin |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PIR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
|
|
G |
Plec |
plectin |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PLEC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:107,887,764...107,949,100
Ensembl chr 7:107,887,764...107,945,467
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PMAIP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects activity |
ISO |
adefovir dipivoxil affects the activity of PPARG protein |
CTD |
PMID:25596134 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppm1d |
protein phosphatase, Mg2+/Mn2+ dependent, 1D |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PPM1D mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:70,172,603...70,208,607
Ensembl chr10:70,172,603...70,208,607
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PRC1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prdm1 |
PR/SET domain 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of PRDM1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
|
|
G |
Prkab2 |
protein kinase AMP-activated non-catalytic subunit beta 2 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of PRKAB2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:185,257,218...185,272,846
Ensembl chr 2:185,257,213...185,269,872
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of PSAT1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Rara |
retinoic acid receptor, alpha |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of RARA mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rps27l |
ribosomal protein S27-like |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of RPS27L mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:67,562,483...67,567,418
Ensembl chr 8:67,562,483...67,567,418 Ensembl chr12:67,562,483...67,567,418 Ensembl chr 2:67,562,483...67,567,418
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of RRM2B mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
Serpinb5 |
serpin family B member 5 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SERPINB5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756
|
|
G |
Sesn1 |
sestrin 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SESN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697
|
|
G |
Sfn |
stratifin |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SFN mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314
|
|
G |
Sh3tc1 |
SH3 domain and tetratricopeptide repeats 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of SH3TC1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr14:75,005,691...75,050,001
Ensembl chr14:75,016,875...75,049,995
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of SLC6A9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Smap1 |
small ArfGAP 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of SMAP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:26,250,178...26,342,151
Ensembl chr 9:26,249,978...26,342,170
|
|
G |
Sulf2 |
sulfatase 2 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of SULF2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:154,822,079...154,904,566
Ensembl chr 3:154,822,085...154,904,415
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
adefovir dipivoxil binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tigar |
TP53 induced glycolysis regulatory phosphatase |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TIGAR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029 Ensembl chr 6:159,927,139...159,946,029
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TIPARP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:149,753,682...149,780,327
Ensembl chr 2:149,753,682...149,780,327
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TNFSF9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:1,944,017...1,946,351
Ensembl chr 9:1,944,017...1,946,345
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
ISO |
adefovir dipivoxil affects the activity of TP53 protein |
CTD |
PMID:25596134 PMID:35435491 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53inp1 |
tumor protein p53 inducible nuclear protein 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TP53INP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968
|
|
G |
Trafd1 |
TRAF type zinc finger domain containing 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of TRAFD1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:35,165,606...35,179,525
Ensembl chr12:35,165,606...35,179,525
|
|
G |
Triap1 |
TP53 regulated inhibitor of apoptosis 1 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of TRIAP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:41,267,534...41,270,053
Ensembl chr12:41,267,549...41,270,042
|
|
G |
Ube2o |
ubiquitin-conjugating enzyme E2O |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of UBE2O mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:101,765,572...101,812,736
Ensembl chr10:101,766,005...101,812,899
|
|
G |
Yars1 |
tyrosyl-tRNA synthetase 1 |
decreases expression |
ISO |
adefovir dipivoxil results in decreased expression of YARS1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:141,535,815...141,564,029
Ensembl chr 5:141,535,759...141,563,833
|
|
G |
Zmat3 |
zinc finger, matrin type 3 |
increases expression |
ISO |
adefovir dipivoxil results in increased expression of ZMAT3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:115,106,966...115,136,863
|
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
Delavirdine results in decreased activity of CYP2C19 protein |
CTD |
PMID:11225565 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Didanosine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Hfe |
homeostatic iron regulator |
multiple interactions |
ISO |
HFE gene SNP affects the susceptibility to [Didanosine co-treated with Stavudine] |
CTD |
PMID:16847405 |
|
NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502
|
|
G |
Il24 |
interleukin 24 |
decreases expression |
ISO |
Didanosine results in decreased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
decreases expression multiple interactions |
ISO |
Didanosine results in decreased expression of COX2 mRNA tenofovir promotes the reaction [Didanosine results in decreased expression of COX2 mRNA] |
CTD |
PMID:16940060 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Slc29a3 |
solute carrier family 29 member 3 |
affects transport |
ISO |
SLC29A3 protein affects the transport of Didanosine |
CTD |
PMID:19164483 |
|
NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Didanosine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
efavirenz inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] efavirenz results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression decreases secretion |
ISO |
efavirenz results in decreased expression of ADIPOQ mRNA efavirenz results in decreased secretion of ADIPOQ protein |
CTD |
PMID:21619898 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Alb |
albumin |
affects binding |
ISO |
efavirenz binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases response to substance increases expression |
ISO |
BCL2L11 protein results in increased susceptibility to efavirenz metabolite efavirenz metabolite results in increased expression of BCL2L11 mRNA; efavirenz metabolite results in increased expression of BCL2L11 protein; efavirenz results in increased expression of BCL2L11 mRNA; efavirenz results in increased expression of BCL2L11 protein |
CTD |
PMID:21958719 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Canx |
calnexin |
affects localization |
ISO |
efavirenz affects the localization of CANX protein |
CTD |
PMID:28940366 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
efavirenz metabolite results in increased cleavage of and results in increased activity of CASP3 protein; efavirenz results in increased cleavage of and results in increased activity of CASP3 protein [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein] |
CTD |
PMID:21958719 PMID:36309141 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in decreased activity of CAT protein |
CTD |
PMID:34118364 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
efavirenz results in increased secretion of CCL2 protein |
CTD |
PMID:21619898 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression |
ISO |
efavirenz results in decreased expression of CEBPA mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects metabolic processing decreases activity multiple interactions increases metabolic processing |
ISO |
CYP2B6 gene polymorphism affects the metabolism of efavirenz; CYP2B6 protein affects the metabolism of efavirenz efavirenz results in decreased activity of CYP2B6 protein [efavirenz results in decreased activity of CYP2B6 protein] which results in decreased metabolism of Bupropion; [efavirenz results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [efavirenz results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA CYP2B6 protein results in increased metabolism of efavirenz |
CTD |
PMID:15622315 PMID:15769884 PMID:17041008 PMID:17559344 PMID:26599973 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
efavirenz results in decreased activity of CYP2C19 protein |
CTD |
PMID:11225565 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity increases expression increases activity |
ISO |
efavirenz results in decreased activity of CYP3A4 protein efavirenz results in increased expression of CYP3A4 mRNA efavirenz results in increased activity of CYP3A4 protein |
CTD |
PMID:15980690 PMID:16837568 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
efavirenz results in increased expression of DDIT3 protein |
CTD |
PMID:28940366 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnm1l |
dynamin 1-like |
affects localization |
ISO |
efavirenz affects the localization of DNM1L protein modified form |
CTD |
PMID:28940366 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
ISO |
efavirenz results in increased expression of EIF2AK3 protein modified form |
CTD |
PMID:28940366 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Fis1 |
fission, mitochondrial 1 |
increases expression |
ISO |
efavirenz results in increased expression of FIS1 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Hgf |
hepatocyte growth factor |
increases secretion |
ISO |
efavirenz results in increased secretion of HGF protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
efavirenz promotes the reaction [VDAC1 protein binds to HSPA9 protein] |
CTD |
PMID:28940366 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein] |
CTD |
PMID:36309141 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
efavirenz results in increased secretion of IL6 protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases phosphorylation |
ISO |
efavirenz metabolite results in increased phosphorylation of JUN protein; efavirenz results in increased phosphorylation of JUN protein |
CTD |
PMID:21958719 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lep |
leptin |
decreases expression |
ISO |
efavirenz results in decreased expression of LEP mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
multiple interactions increases expression increases response to substance |
ISO |
efavirenz results in increased expression of and affects the localization of LONP1 protein; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [efavirenz results in increased expression of LONP1 mRNA] LONP1 protein results in increased susceptibility to efavirenz |
CTD |
PMID:28940366 |
|
NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
ISO |
efavirenz results in decreased expression of LPL mRNA |
CTD |
PMID:21619898 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
increases phosphorylation |
ISO |
efavirenz metabolite results in increased phosphorylation of MAP3K5 protein; efavirenz results in increased phosphorylation of MAP3K5 protein |
CTD |
PMID:21958719 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [efavirenz metabolite results in increased phosphorylation of MAPK8 protein]; Acetylcysteine inhibits the reaction [efavirenz results in increased phosphorylation of MAPK8 protein] efavirenz metabolite results in increased phosphorylation of MAPK8 protein; efavirenz results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:21958719 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mfn2 |
mitofusin 2 |
increases expression |
ISO |
efavirenz results in increased expression of MFN2 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of MPO protein |
CTD |
PMID:34118364 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
EXP |
efavirenz results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases activity |
ISO EXP |
[efavirenz results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [efavirenz results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 PMID:27732639 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
increases expression |
ISO |
efavirenz results in increased expression of OPA1 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
efavirenz results in decreased expression of PPARG mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
increases expression |
ISO |
efavirenz results in increased expression of RMDN3 protein |
CTD |
PMID:28940366 |
|
NCBI chr 3:106,125,961...106,146,568
Ensembl chr 3:106,125,951...106,146,586
|
|
G |
Serpine1 |
serpin family E member 1 |
increases secretion |
ISO |
efavirenz results in increased secretion of SERPINE1 protein |
CTD |
PMID:21619898 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
[efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 protein |
CTD |
PMID:16030158 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
efavirenz results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21619898 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tg |
thyroglobulin |
increases expression |
ISO |
efavirenz results in increased expression of TG mRNA; efavirenz results in increased expression of TG protein |
CTD |
PMID:16030158 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein] |
CTD |
PMID:36309141 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tpo |
thyroid peroxidase |
increases expression |
ISO |
efavirenz results in increased expression of TPO mRNA; efavirenz results in increased expression of TPO protein |
CTD |
PMID:16030158 |
|
NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [efavirenz co-treated with TSHB protein] results in increased expression of SLC5A5 protein; efavirenz promotes the reaction [TSHB protein affects the abundance of Iodine]; sodium perchlorate inhibits the reaction [efavirenz promotes the reaction [TSHB protein affects the abundance of Iodine]] |
CTD |
PMID:16030158 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
increases expression |
ISO |
efavirenz results in increased expression of TSHR mRNA |
CTD |
PMID:16030158 |
|
NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
efavirenz promotes the reaction [VDAC1 protein binds to HSPA9 protein] |
CTD |
PMID:28940366 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Emtricitabine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of CDKN1A protein |
CTD |
PMID:31545371 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions affects binding |
ISO |
DCK protein results in increased phosphorylation of and results in increased activity of Emtricitabine Emtricitabine binds to DCK protein |
CTD |
PMID:17530837 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
decreases expression multiple interactions |
ISO |
Emtricitabine results in decreased expression of PRKN protein [Emtricitabine co-treated with Tenofovir] results in decreased expression of PRKN protein |
CTD |
PMID:31545371 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of TP53 protein |
CTD |
PMID:31545371 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ACADSB mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
|
|
G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ACSL6 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
Lamivudine results in decreased expression of ACTA2 protein |
CTD |
PMID:11738102 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:16931933 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Aebp1 |
AE binding protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of AEBP1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of AEBP1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr14:80,738,800...80,748,878
Ensembl chr14:80,738,892...80,748,877
|
|
G |
Afap1 |
actin filament associated protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of AFAP1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr14:74,743,322...74,856,300
Ensembl chr14:74,743,320...74,856,263
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Lamivudine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ALOX5AP mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ALOX5AP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of AQP9 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Arpp21 |
cAMP regulated phosphoprotein 21 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ARPP21 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ARPP21 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:112,034,636...112,199,273
Ensembl chr 8:112,034,642...112,194,297
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ASIC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ASIC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:65,870,592...66,940,577
Ensembl chr10:65,870,594...66,940,424
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ASNS mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ASS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATF3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ATP2A2 mRNA |
CTD |
PMID:11706060 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5F1C mRNA |
CTD |
PMID:18313992 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Atp5mc3 |
ATP synthase membrane subunit c locus 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ATP5MC3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279
|
|
G |
Atp5mf |
ATP synthase membrane subunit f |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5MF mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5PD mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ATP5PF mRNA |
CTD |
PMID:18313992 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
Atp5po |
ATP synthase peripheral stalk subunit OSCP |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ATP5PO mRNA |
CTD |
PMID:18313992 |
|
NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of BCL2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Lamivudine results in increased expression of BNIP3L protein |
CTD |
PMID:23640862 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
C1r |
complement C1r |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C1R mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C1R mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of C3AR1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of C3AR1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
Cars1 |
cysteinyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:198,753,689...198,796,016
Ensembl chr 1:198,753,691...198,795,941
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein] |
CTD |
PMID:36309141 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in decreased activity of CAT protein |
CTD |
PMID:34118364 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNA2 mRNA Lamivudine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnc |
cyclin C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNC mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CCND1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression multiple interactions |
ISO |
Lamivudine results in decreased expression of CCND2 mRNA [Zidovudine co-treated with Lamivudine] results in decreased expression of CCND2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne2 |
cyclin E2 |
multiple interactions decreases expression |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CCNE2 mRNA Lamivudine results in decreased expression of CCNE2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CD36 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CD36 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CD44 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd83 |
CD83 molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CD83 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CDK7 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:31,840,558...31,865,422
Ensembl chr 2:31,840,558...31,865,383
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
ISO |
Lamivudine results in decreased expression of CDKN1A mRNA [Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1A mRNA |
CTD |
PMID:15784690 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CFD mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CIDEC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CIDEC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of CLCN3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of CLCN3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Lamivudine results in decreased expression of COL3A1 protein |
CTD |
PMID:11738102 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COMT mRNA |
CTD |
PMID:15784690 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of COX5A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX5B mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052
|
|
G |
Cox6a1 |
cytochrome c oxidase subunit 6A1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX6A1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041
|
|
G |
Cox6c |
cytochrome c oxidase subunit 6C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX6C mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:67,129,265...67,142,001
Ensembl chr 7:67,111,024...67,141,963
|
|
G |
Cox7c |
cytochrome c oxidase subunit 7C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX7C mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CPT1A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crat |
carnitine O-acetyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CRAT mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Cul7 |
cullin 7 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CUL7 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:14,319,102...14,333,035
Ensembl chr 9:14,319,108...14,332,741
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of CYB5A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Dck |
deoxycytidine kinase |
multiple interactions |
ISO |
DCK protein results in increased phosphorylation of and results in increased activity of Lamivudine |
CTD |
PMID:17530837 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Dcn |
decorin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DCN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DCN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
Lamivudine results in increased expression of DDIT3 mRNA [Zidovudine co-treated with Lamivudine] results in increased expression of DDIT3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dhfr |
dihydrofolate reductase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of DHFR mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of DIABLO mRNA |
CTD |
PMID:18313992 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of DLST mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dnaja3 |
DnaJ heat shock protein family (Hsp40) member A3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of DNAJA3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:10,854,732...10,880,171
Ensembl chr10:10,854,732...10,880,161
|
|
G |
Dusp3 |
dual specificity phosphatase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of DUSP3 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of DUSP3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of ECHS1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ECI1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases secretion |
ISO |
coenzyme Q10 inhibits the reaction [Lamivudine results in increased secretion of EDN1 protein] |
CTD |
PMID:23640862 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of EIF4EBP1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elovl3 |
ELOVL fatty acid elongase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ELOVL3 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of ELOVL3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:244,997,287...245,001,115
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of ESR2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of ESR2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of ETV6 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of ETV6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FADS2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of FADS2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of FAIM mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of FAIM mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:99,543,877...99,569,499
Ensembl chr 8:99,542,405...99,560,562
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of FASN mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of FASN mRNA |
CTD |
PMID:11741158 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fdxr |
ferredoxin reductase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of FDXR mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fh |
fumarate hydratase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of FH1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
|
|
G |
G0s2 |
G0/G1switch 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of G0S2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of G0S2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of G6PC1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Ganc |
glucosidase, alpha; neutral C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of GANC mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of GANC mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 3:107,353,369...107,406,104
Ensembl chr 3:107,353,369...107,405,241
|
|
G |
Gars1 |
glycyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of GARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of GAS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr17:4,482,168...4,485,153
|
|
G |
Grhl2 |
grainyhead-like transcription factor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of GRHL2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:68,400,287...68,530,269
Ensembl chr 7:68,400,477...68,530,258
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of GUCY1B1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of GUCY1B1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:167,348,824...167,398,983
Ensembl chr 2:167,348,825...167,398,916
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased mutagenesis of GYPA gene |
CTD |
PMID:17358027 |
|
NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of HADH mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of HADH mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HADHA mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hax1 |
HCLS1 associated protein X-1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HAX1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714
|
|
G |
Hcn1 |
hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of HCN1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of HCN1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:49,495,771...49,899,983
Ensembl chr 2:49,495,771...49,899,774
|
|
G |
Hist1h4b |
histone cluster 1 H4 family member B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of H4C9 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of H4C9 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of HRK mRNA |
CTD |
PMID:16931933 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hsd3b3 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of HSD3B3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:186,138,044...186,144,024
Ensembl chr 2:186,138,044...186,144,033
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IDH2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IDH3A mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Idh3g |
isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of IDH3G mRNA |
CTD |
PMID:18313992 |
|
NCBI chr X:151,515,244...151,524,175
Ensembl chr X:151,515,247...151,524,171
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
Lamivudine results in increased expression of IFNG protein |
CTD |
PMID:16250037 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikzf4 |
IKAROS family zinc finger 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of IKZF4 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of IKZF4 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:1,063,283...1,102,940
Ensembl chr 7:1,056,890...1,084,341
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein] |
CTD |
PMID:36309141 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il27ra |
interleukin 27 receptor subunit alpha |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of IL27RA mRNA |
CTD |
PMID:15784690 |
|
NCBI chr19:24,109,963...24,121,977
Ensembl chr19:24,109,972...24,121,938
|
|
G |
Inpp5e |
inositol polyphosphate-5-phosphatase E |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of INPP5E mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:9,216,776...9,229,539
Ensembl chr 3:9,216,776...9,229,450
|
|
G |
Kcng1 |
potassium voltage-gated channel modifier subfamily G member 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KCNG1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:156,960,717...156,992,877
Ensembl chr 3:156,973,156...156,992,635
|
|
G |
Kifc2 |
kinesin family member C2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of KIFC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:108,380,634...108,388,364
Ensembl chr 7:108,376,011...108,388,484
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KLF4 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klhl28 |
kelch-like family member 28 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of KLHL28 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of KLHL28 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 6:82,987,360...83,018,971
Ensembl chr 6:82,990,945...83,016,164
|
|
G |
Krt7 |
keratin 7 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KRT7 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052
|
|
G |
Kynu |
kynureninase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of KYNU mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lamb3 |
laminin subunit beta 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of LAMB3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of LAMC2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of LAMC2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of LEF1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LEP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of LEP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression multiple interactions |
ISO |
Lamivudine results in decreased expression of LPL mRNA [Stavudine co-treated with Lamivudine co-treated with Indinavir] affects the expression of LPL mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of LPL mRNA; [Stavudine co-treated with Lamivudine] affects the expression of LPL mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of LPL mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of LPL mRNA |
CTD |
PMID:11741158 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mars1 |
methionyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of MARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 7:63,121,142...63,138,550
Ensembl chr 7:63,121,142...63,138,495
|
|
G |
Me1 |
malic enzyme 1 |
multiple interactions increases expression |
ISO |
[Stavudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine co-treated with Nelfinavir] results in decreased expression of ME1 mRNA; [Stavudine co-treated with Lamivudine] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of ME1 mRNA; [Zidovudine co-treated with Lamivudine] affects the expression of ME1 mRNA Lamivudine results in increased expression of ME1 mRNA |
CTD |
PMID:11741158 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of MFN1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of MFN2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mgat4c |
MGAT4 family, member C |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MGAT4C mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of MGAT4C mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of MGAT4C mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:36,709,564...37,485,810
Ensembl chr 7:37,260,321...37,474,571
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Lamivudine results in increased expression of MMP1 protein |
CTD |
PMID:15309715 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of MPO protein |
CTD |
PMID:34118364 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mrap |
melanocortin 2 receptor accessory protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of MRAP mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of MRAP mRNA |
CTD |
PMID:16931933 |
|
NCBI chr11:29,991,974...30,003,024
Ensembl chr11:29,992,034...30,003,024
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of COX1 mRNA |
CTD |
PMID:17526437 PMID:18313992 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of COX2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Mt-co3 |
mitochondrially encoded cytochrome c oxidase III |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of COX3 mRNA |
CTD |
PMID:17526437 PMID:18313992 |
|
NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
|
|
G |
Mt-nd2 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ND2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942 NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942
|
|
G |
Mt-nd5 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of ND5 mRNA |
CTD |
PMID:17526437 PMID:18313992 |
|
NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565 NCBI chr MT:11,736...13,565
Ensembl chr MT:11,736...13,565
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of MTHFD2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Myod1 |
myogenic differentiation 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of MYOD1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of MYOD1 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of MYOD1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Nap1l5 |
nucleosome assembly protein 1-like 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NAP1L5 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of NAP1L5 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of NAP1L5 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:88,022,670...88,024,988
Ensembl chr 4:88,022,569...88,024,654
|
|
G |
Ndufa4 |
Ndufa4, mitochondrial complex associated |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFA4 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920
|
|
G |
Ndufab1 |
NADH:ubiquinone oxidoreductase subunit AB1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFAB1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:176,644,696...176,658,131
Ensembl chr 1:176,644,703...176,658,099
|
|
G |
Ndufaf1 |
NADH:ubiquinone oxidoreductase complex assembly factor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFAF1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:106,639,025...106,650,549
Ensembl chr 3:106,639,851...106,650,212
|
|
G |
Ndufb3 |
NADH:ubiquinone oxidoreductase subunit B3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of NDUFB3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:60,129,240...60,139,452
Ensembl chr 9:60,129,154...60,139,446
|
|
G |
Ndufb5 |
NADH:ubiquinone oxidoreductase subunit B5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of NDUFB5 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:115,519,248...115,533,589
Ensembl chr 2:115,519,154...115,533,589
|
|
G |
Ndufb9 |
NADH:ubiquinone oxidoreductase subunit B9 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFB9 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:90,480,948...90,487,367
Ensembl chr 7:90,436,621...90,488,009
|
|
G |
Ndufc1 |
NADH:ubiquinone oxidoreductase subunit C1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFC1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 2:135,447,067...135,450,950
Ensembl chr 2:135,447,119...135,450,874
|
|
G |
Ndufs1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NDUFS1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NIBAN1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
|
|
G |
Noct |
nocturnin |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of NOCT mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of NOCT mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of NOCT mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases phosphorylation |
ISO |
coenzyme Q10 inhibits the reaction [Lamivudine results in decreased phosphorylation of NOS3 protein] |
CTD |
PMID:23640862 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NPPA mRNA |
CTD |
PMID:11706060 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nup210 |
nucleoporin 210 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of NUP210 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of NUP210 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of NUP210 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 4:123,511,558...123,609,874
Ensembl chr 4:123,511,559...123,609,874
|
|
G |
Nxnl2 |
nucleoredoxin-like 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of NXNL2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr17:14,031,151...14,035,897
Ensembl chr17:14,031,153...14,036,189
|
|
G |
Oaz3 |
ornithine decarboxylase antizyme 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of OAZ3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of OAZ3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:182,073,212...182,076,147
Ensembl chr 2:182,073,215...182,082,399
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of OGT mRNA |
CTD |
PMID:15784690 |
|
NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of OPA1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of OPRL1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920
|
|
G |
Pcdh15 |
protocadherin related 15 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PCDH15 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PCDH15 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of PCDH15 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of PCK2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PFKFB3 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of PFKFB3 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
|
|
G |
Pgap6 |
post-GPI attachment to proteins 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of PGAP6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:15,138,918...15,148,431
Ensembl chr10:15,138,959...15,148,431
|
|
G |
Phf6 |
PHD finger protein 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of PHF6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of PHF6 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of PHF6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr X:132,656,658...132,699,720
Ensembl chr X:132,656,672...132,699,127
|
|
G |
Pidd1 |
p53-induced death domain protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIDD1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PIDD1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 1:196,536,815...196,542,808
Ensembl chr 1:196,536,834...196,542,699
|
|
G |
Piwil2 |
piwi-like RNA-mediated gene silencing 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PIWIL2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PIWIL2 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of PIWIL2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr15:45,431,402...45,498,034
Ensembl chr15:45,431,703...45,497,702
|
|
G |
Porcn |
porcupine O-acyltransferase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PPN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PPN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr X:14,285,864...14,298,481
Ensembl chr X:14,285,871...14,298,481
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of POU5F1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of POU5F1 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of POU5F1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Prdm1 |
PR/SET domain 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of PRDM1 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of PRDM1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of PSAT1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Rabepk |
Rab9 effector protein with kelch motifs |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of RABEPK mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:18,061,299...18,083,191
Ensembl chr 3:18,061,574...18,083,191
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of RBL1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of RBL2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572
|
|
G |
Reep6 |
receptor accessory protein 6 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of REEP6 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of REEP6 mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of REEP6 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 7:9,373,927...9,380,845
Ensembl chr 7:9,373,927...9,380,597
|
|
G |
Ripk2 |
receptor-interacting serine-threonine kinase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of RIPK2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:29,630,806...29,662,804
Ensembl chr 5:29,631,570...29,662,657
|
|
G |
Rnf151 |
ring finger protein 151 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of RNF151 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of RNF151 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of RNF151 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:13,742,682...13,747,192
Ensembl chr10:13,742,682...13,745,000
|
|
G |
Rpain |
RPA interacting protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of RPAIN mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of RPAIN mRNA; [Zidovudine co-treated with Lamivudine] results in decreased expression of RPAIN mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:55,692,410...55,699,910
Ensembl chr10:55,692,417...55,699,933
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in decreased expression of S100A8 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in decreased expression of S100A8 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SDHB mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
|
|
G |
Serinc1 |
serine incorporator 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SERINC1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr20:36,850,062...36,868,999
Ensembl chr20:36,850,076...36,896,691
|
|
G |
Sfxn1 |
sideroflexin 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SFXN1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr17:10,486,250...10,522,640
Ensembl chr17:10,486,271...10,522,529
|
|
G |
Sfxn2 |
sideroflexin 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SFXN2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411 Ensembl chr 1:245,447,015...245,468,411
|
|
G |
Sfxn4 |
sideroflexin 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SFXN4 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:259,976,480...259,998,778
Ensembl chr 1:259,976,481...259,998,754
|
|
G |
Sgpp1 |
sphingosine-1-phosphate phosphatase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SGPP1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:94,425,339...94,446,534
Ensembl chr 6:94,425,339...94,446,534
|
|
G |
Slc1a4 |
solute carrier family 1 member 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC1A4 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr14:94,530,801...94,560,190
Ensembl chr14:94,529,084...94,560,418
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC1A5 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
increases uptake |
ISO |
SLC22A1 protein results in increased uptake of Lamivudine |
CTD |
PMID:19141712 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
increases uptake |
ISO |
SLC22A2 protein results in increased uptake of Lamivudine |
CTD |
PMID:19141712 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
increases uptake |
ISO |
SLC22A3 protein results in increased uptake of Lamivudine |
CTD |
PMID:19141712 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc25a12 |
solute carrier family 25 member 12 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A12 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 3:56,097,166...56,191,841
Ensembl chr 3:56,097,269...56,192,100
|
|
G |
Slc25a15 |
solute carrier family 25 member 15 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A15 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr16:69,631,581...69,654,869
Ensembl chr16:69,634,414...69,653,010
|
|
G |
Slc25a19 |
solute carrier family 25 member 19 |
multiple interactions |
ISO |
SLC25A19 protein affects the susceptibility to [Stavudine co-treated with Lamivudine co-treated with Indinavir]; SLC25A19 protein affects the susceptibility to [Zidovudine co-treated with Lamivudine co-treated with Indinavir] [Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A19 mRNA |
CTD |
PMID:15951836 PMID:18313992 |
|
NCBI chr10:100,853,554...100,867,517
Ensembl chr10:100,847,168...100,867,447
|
|
G |
Slc25a2 |
solute carrier family 25 member 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr18:29,452,943...29,456,324
Ensembl chr18:29,453,582...29,460,383
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A20 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G |
Slc25a29 |
solute carrier family 25 member 29 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A29 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 6:127,742,027...127,752,915
Ensembl chr 6:127,742,033...127,752,940
|
|
G |
Slc25a3 |
solute carrier family 25 member 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of SLC25A3 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:25,611,937...25,619,401
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Slc25a4 |
solute carrier family 25 member 4 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC25A4 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
multiple interactions |
ISO |
Lamivudine inhibits the reaction [SLC28A1 protein results in increased transport of Uridine] |
CTD |
PMID:10772724 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC31A1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC3A2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SLC40A1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions increases expression |
ISO |
[Lamivudine co-treated with IFNA2 protein] results in increased expression of SLC6A4 mRNA; Lamivudine promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]; Lamivudine results in increased expression of and results in increased activity of SLC6A4 protein Lamivudine results in increased expression of SLC6A4 mRNA |
CTD |
PMID:16476009 |
|
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Spink5 |
serine peptidase inhibitor, Kazal type 5 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of SPINK5 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of SPINK5 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of SPINK5 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr18:36,264,452...36,333,143
Ensembl chr18:36,264,452...36,332,185
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of STAR mRNA |
CTD |
PMID:18313992 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stc2 |
stanniocalcin 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of STC2 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Sub1 |
SUB1 regulator of transcription |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of SUB1 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 2:61,005,646...61,020,486
Ensembl chr 2:61,005,666...61,020,436 Ensembl chr 2:61,005,666...61,020,436
|
|
G |
Tcea1 |
transcription elongation factor A1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TCEA1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:14,631,454...14,668,769
Ensembl chr 5:14,631,454...14,668,745 Ensembl chr15:14,631,454...14,668,745
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
Lamivudine results in decreased expression of TGFB1 protein |
CTD |
PMID:15309715 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timm17b |
translocase of inner mitochondrial membrane 17b |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TIMM17B mRNA |
CTD |
PMID:18313992 |
|
NCBI chr X:14,596,330...14,603,491
Ensembl chr X:14,594,577...14,603,416
|
|
G |
Timm23 |
translocase of inner mitochondrial membrane 23 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TIMM23 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr16:7,410,308...7,436,392
Ensembl chr16:7,409,688...7,436,379 Ensembl chr 3:7,409,688...7,436,379 Ensembl chr 6:7,409,688...7,436,379
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
ISO |
Lamivudine results in decreased expression of TIMP1 protein |
CTD |
PMID:15309715 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TIMP2 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of TIMP2 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of TIMP2 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tk2 |
thymidine kinase 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TK2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr19:708,859...731,786
Ensembl chr19:708,891...730,924
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein] |
CTD |
PMID:36309141 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of TRIB3 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Trim42 |
tripartite motif-containing 42 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of TRIM42 mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of TRIM42 mRNA; [Zidovudine co-treated with Lamivudine] results in increased expression of TRIM42 mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 8:97,902,349...97,923,268
Ensembl chr 8:97,902,353...97,923,268
|
|
G |
Twnk |
twinkle mtDNA helicase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of TWNK mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:243,867,568...243,874,802
Ensembl chr 1:243,868,330...243,874,802
|
|
G |
Tyms |
thymidylate synthetase |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of TYMS mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of TYRP1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Uqcrb |
ubiquinol-cytochrome c reductase binding protein |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of UQCRB mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 7:63,814,784...63,820,150
Ensembl chr 7:63,814,797...63,820,150
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of UQCRC1 mRNA |
CTD |
PMID:17526437 PMID:18313992 |
|
NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Uqcrc2 |
ubiquinol cytochrome c reductase core protein 2 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of UQCRC2 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of VDAC1 mRNA |
CTD |
PMID:18313992 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of VDR mRNA |
CTD |
PMID:11741158 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vps4b |
vacuolar protein sorting 4 homolog B |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in decreased expression of VPS4B mRNA |
CTD |
PMID:16931933 |
|
NCBI chr13:22,907,105...22,932,200
Ensembl chr13:22,907,109...22,932,229
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of WARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Wnt10a |
Wnt family member 10A |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine co-treated with Indinavir] results in increased expression of WNT10A mRNA; [Zidovudine co-treated with Lamivudine co-treated with Saquinavir] results in increased expression of WNT10A mRNA |
CTD |
PMID:16931933 |
|
NCBI chr 9:76,349,931...76,362,400
Ensembl chr 9:76,349,931...76,362,400
|
|
G |
Yars1 |
tyrosyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Zidovudine co-treated with Lamivudine] results in increased expression of YARS1 mRNA |
CTD |
PMID:15784690 |
|
NCBI chr 5:141,535,815...141,564,029
Ensembl chr 5:141,535,759...141,563,833
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Nevirapine results in increased expression of ABCB1A mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Adamts15 |
ADAM metallopeptidase with thrombospondin type 1 motif, 15 |
increases expression |
ISO |
Nevirapine results in increased expression of ADAMTS15 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:29,307,865...29,331,249
|
|
G |
Adamts9 |
ADAM metallopeptidase with thrombospondin type 1 motif, 9 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of ADAMTS9 mRNA; Nevirapine results in decreased expression of ADAMTS9 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:125,290,633...125,462,988
Ensembl chr 4:125,291,490...125,462,929
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of ADGRF5 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression increases secretion |
ISO |
Nevirapine results in increased expression of ADIPOQ mRNA Nevirapine results in increased secretion of ADIPOQ protein |
CTD |
PMID:21619898 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases expression |
ISO |
Nevirapine results in increased expression of ADRB2 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of AIF1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
Nevirapine results in increased expression of ALAS1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Nevirapine binds to ALB protein |
CTD |
PMID:15814459 PMID:16336266 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression |
ISO |
Nevirapine results in increased expression of APOA1 protein |
CTD |
PMID:19667106 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Ar |
androgen receptor |
increases expression |
ISO |
Nevirapine results in increased expression of AR mRNA; Nevirapine results in increased expression of AR protein |
CTD |
PMID:19152342 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Armcx2 |
armadillo repeat containing, X-linked 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of ARMCX2 mRNA; Nevirapine results in decreased expression of ARMCX2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr X:97,980,662...97,985,523
Ensembl chr X:97,980,660...97,985,552
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of ARNT mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
decreases expression |
ISO |
Nevirapine results in decreased expression of ARRDC3 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
increases expression |
ISO |
Nevirapine results in increased expression of ATP1B1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Nevirapine results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Nevirapine results in increased cleavage of CASP3 protein Mifepristone inhibits the reaction [Nevirapine results in increased cleavage of CASP3 protein] |
CTD |
PMID:38636494 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cd180 |
CD180 molecule |
decreases expression |
ISO |
Nevirapine results in decreased expression of CD180 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:33,855,991...33,899,936
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of CD36 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Nevirapine results in increased expression of CDKN1A mRNA |
CTD |
PMID:38636494 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
Nevirapine results in increased expression of CEBPA mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression |
EXP |
Nevirapine results in increased expression of CES2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
increases expression |
ISO |
Nevirapine results in increased expression of CIITA |
CTD |
PMID:26626330 |
|
NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
decreases expression |
ISO |
Nevirapine results in decreased expression of CISH mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
Nevirapine results in decreased expression of CLDN5 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Clec4a1 |
C-type lectin domain family 4, member A1 |
decreases expression |
EXP |
Nevirapine results in decreased expression of CLEC4A1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:156,173,894...156,186,009
Ensembl chr 4:156,173,894...156,186,008
|
|
G |
Clec4a3 |
C-type lectin domain family 4, member A3 |
decreases expression |
EXP |
Nevirapine results in decreased expression of CLEC4A3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:156,214,030...156,224,818
Ensembl chr 4:156,214,718...156,224,817
|
|
G |
Clec4m |
C-type lectin domain family 4 member M |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of CD209B mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:1,915,902...1,924,529
Ensembl chr12:1,915,919...1,924,539
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
EXP |
Nevirapine results in decreased expression of COTL1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cux2 |
cut-like homeobox 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of CUX2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:34,507,723...34,707,581
Ensembl chr12:34,520,959...34,705,806
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression |
ISO |
Nevirapine results in decreased expression of CXCL1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of CYP2B1 mRNA; Nevirapine results in increased expression of CYP2B1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
[Nevirapine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Nevirapine results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA Nevirapine results in increased expression of CYP2B10 mRNA |
CTD |
PMID:17041008 PMID:38636494 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects binding |
EXP |
Nevirapine binds to CYP2C11 protein |
CTD |
PMID:22793666 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects binding |
ISO |
Nevirapine binds to CYP3A4 protein |
CTD |
PMID:22793666 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
affects binding increases expression |
EXP |
Nevirapine binds to CYP3A23-3A1 protein Nevirapine results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:22793666 PMID:23947594 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
EXP |
Nevirapine results in increased expression of CYP3A9 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of CYP4B1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Dapk1 |
death associated protein kinase 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of DAPK1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of DBP mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
decreases expression |
ISO |
Nevirapine results in decreased expression of DCLK3 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 8:111,401,544...111,453,999
Ensembl chr 8:111,401,358...111,453,999
|
|
G |
Ddhd1 |
DDHD domain containing 1 |
decreases expression |
EXP |
Nevirapine results in decreased expression of DDHD1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr15:18,824,389...18,891,036
Ensembl chr15:18,824,394...18,890,952
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
Nevirapine results in increased expression of DDIT4 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Depdc7 |
DEP domain containing 7 |
decreases expression |
ISO |
Nevirapine results in decreased expression of DEPDC7 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 3:91,099,111...91,121,152
Ensembl chr 3:91,099,835...91,121,124
|
|
G |
Dip2a |
disco-interacting protein 2 homolog A |
increases expression |
EXP |
Nevirapine results in increased expression of DIP2A mRNA |
CTD |
PMID:23947594 |
|
NCBI chr20:12,284,566...12,371,068
Ensembl chr20:12,284,654...12,370,217
|
|
G |
Dnajb5 |
DnaJ heat shock protein family (Hsp40) member B5 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of DNAJB5 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:57,176,840...57,186,067
Ensembl chr 5:57,176,845...57,185,490
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Nevirapine results in increased expression of DUSP1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Edem1 |
ER degradation enhancing alpha-mannosidase like protein 1 |
increases expression |
EXP |
Nevirapine results in increased expression of EDEM1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
Nevirapine results in decreased expression of EGF mRNA |
CTD |
PMID:19152342 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Nevirapine results in decreased expression of EGFR mRNA |
CTD |
PMID:19152342 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
decreases expression |
EXP |
Nevirapine results in decreased expression of EPB41L3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Nevirapine results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of ESM1 mRNA; Nevirapine results in increased expression of ESM1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:44,876,067...44,884,805
Ensembl chr 2:44,876,067...44,884,804
|
|
G |
Fam107a |
family with sequence similarity 107, member A |
increases expression |
EXP |
Nevirapine results in increased expression of FAM107A mRNA |
CTD |
PMID:23947594 |
|
NCBI chr15:16,608,362...16,630,398
Ensembl chr15:16,607,205...16,630,396
|
|
G |
Fibin |
fin bud initiation factor homolog |
increases expression |
EXP |
Nevirapine results in increased expression of FIBIN mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 3:96,942,405...96,944,676
Ensembl chr 3:96,942,406...96,944,676
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of FKBP5 mRNA; Nevirapine results in increased expression of FKBP5 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of FMO1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Foxo1 |
forkhead box O1 |
increases expression |
ISO |
Nevirapine results in increased expression of FOXO1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
increases expression |
EXP ISO |
Nevirapine results in increased expression of GADD45B mRNA |
CTD |
PMID:23947594 PMID:38636494 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions increases expression |
ISO |
Nevirapine results in increased expression of and results in increased secretion of GDF15 protein Nevirapine results in increased expression of GDF15 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of GLUL mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Mifepristone inhibits the reaction [Nevirapine results in increased secretion of and results in increased activity of GPT protein]; Nevirapine results in increased secretion of and results in increased activity of GPT protein |
CTD |
PMID:38636494 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases glutathionylation |
ISO |
GSTA1 protein results in increased glutathionylation of Nevirapine metabolite |
CTD |
PMID:27989146 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases glutathionylation |
ISO |
GSTM1 protein results in increased glutathionylation of Nevirapine metabolite |
CTD |
PMID:27989146 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases glutathionylation |
ISO |
GSTP1 protein results in increased glutathionylation of Nevirapine metabolite |
CTD |
PMID:27989146 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gzma |
granzyme A |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of GZMA mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:44,740,569...44,752,493
|
|
G |
Gzmf |
granzyme F |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of GZMF mRNA |
CTD |
PMID:23947594 |
|
NCBI chr15:30,005,361...30,018,649
Ensembl chr15:30,007,267...30,018,649
|
|
G |
Hao2 |
hydroxyacid oxidase 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of HAO2 mRNA; Nevirapine results in decreased expression of HAO2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:186,200,137...186,232,997
Ensembl chr 2:186,200,504...186,224,425
|
|
G |
Hdc |
histidine decarboxylase |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of HDC mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 3:113,847,256...113,865,334
Ensembl chr 3:113,847,260...113,865,341
|
|
G |
Hgf |
hepatocyte growth factor |
decreases secretion |
ISO |
Nevirapine results in decreased secretion of HGF protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of HMGCS2 mRNA; Nevirapine results in increased expression of HMGCS2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of HPGD mRNA |
CTD |
PMID:23947594 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of HSD17B2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
increases expression |
ISO |
Nevirapine results in increased expression of HSPA2 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO EXP |
Nevirapine results in increased expression of IFNG protein |
CTD |
PMID:23947594 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression multiple interactions |
ISO |
Nevirapine results in increased expression of IGFBP1 mRNA Nevirapine results in increased expression of and results in increased secretion of IGFBP1 protein |
CTD |
PMID:38636494 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igh-6 |
immunoglobulin heavy chain 6 |
increases expression |
EXP |
Nevirapine results in increased expression of IGH-6 mRNA |
CTD |
PMID:23947594 |
|
|
|
G |
Ihh |
Indian hedgehog signaling molecule |
decreases expression |
ISO |
Nevirapine results in decreased expression of IHH mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 9:76,504,315...76,510,532
Ensembl chr 9:76,504,315...76,510,532
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Nevirapine results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
increases expression |
ISO |
Nevirapine results in increased expression of IL1R1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il22ra2 |
interleukin 22 receptor subunit alpha 2 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of IL22RA2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:14,353,736...14,377,844
Ensembl chr 1:14,364,489...14,377,844
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Nevirapine results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
decreases secretion |
ISO |
Nevirapine results in decreased secretion of IL6 protein |
CTD |
PMID:21619898 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhbe |
inhibin subunit beta E |
decreases expression |
EXP ISO |
Nevirapine metabolite results in decreased expression of INHBE mRNA Nevirapine results in decreased expression of INHBE mRNA |
CTD |
PMID:23947594 PMID:38636494 |
|
NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Inmt |
indolethylamine N-methyltransferase |
increases expression |
EXP |
Nevirapine results in increased expression of INMT mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:84,318,197...84,322,493
Ensembl chr 4:84,318,197...84,322,493
|
|
G |
Insig2 |
insulin induced gene 2 |
increases expression |
EXP |
Nevirapine results in increased expression of INSIG2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923
|
|
G |
Irf1 |
interferon regulatory factor 1 |
decreases expression |
ISO |
Nevirapine results in decreased expression of IRF1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Irgm |
immunity-related GTPase M |
decreases expression |
EXP |
Nevirapine results in decreased expression of IRGM mRNA |
CTD |
PMID:23947594 |
|
NCBI chr10:33,233,513...33,241,594
Ensembl chr10:33,233,455...33,241,578
|
|
G |
Itga2 |
integrin subunit alpha 2 |
increases expression |
ISO |
Nevirapine results in increased expression of ITGA2 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases expression |
EXP |
Nevirapine results in increased expression of ITPR1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Nevirapine results in increased expression of JUN mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf15 |
KLF transcription factor 15 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of KLF15 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
increases expression |
ISO |
Nevirapine results in increased expression of KLK3 mRNA; Nevirapine results in increased expression of KLK3 protein |
CTD |
PMID:19152342 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Krt18 |
keratin 18 |
increases expression |
ISO |
Nevirapine results in increased expression of KRT18 protein |
CTD |
PMID:19152342 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 Ensembl chr10:133,157,475...133,161,166
|
|
G |
Krt23 |
keratin 23 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of KRT23 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr10:84,434,445...84,450,773
Ensembl chr10:84,434,380...84,450,983
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases expression |
ISO |
Nevirapine results in increased expression of LCAT protein |
CTD |
PMID:19667106 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
Nevirapine results in increased expression of LCN2 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldaf1 |
lipid droplet assembly factor 1 |
decreases expression |
EXP |
Nevirapine results in decreased expression of LDAF1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:174,484,438...174,503,037
Ensembl chr 1:174,484,447...174,503,036
|
|
G |
Lep |
leptin |
increases expression |
ISO |
Nevirapine results in increased expression of LEP mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lhfpl2 |
LHFPL tetraspan subfamily member 2 |
decreases expression |
ISO |
Nevirapine results in decreased expression of LHFPL2 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 2:25,281,771...25,428,128
Ensembl chr 2:25,281,901...25,427,950
|
|
G |
Lifr |
LIF receptor subunit alpha |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of LIFR mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
|
|
G |
Lipg |
lipase G, endothelial type |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of LIPG mRNA; Nevirapine results in decreased expression of LIPG mRNA |
CTD |
PMID:23947594 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
G |
Lpin1 |
lipin 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of LPIN1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
Nevirapine results in increased expression of LPL mRNA |
CTD |
PMID:21619898 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrg1 |
leucine-rich alpha-2-glycoprotein 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of LRG1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813
|
|
G |
Ly86 |
lymphocyte antigen 86 |
decreases expression |
EXP |
Nevirapine results in decreased expression of LY86 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260
|
|
G |
Meox2 |
mesenchyme homeobox 2 |
increases expression |
EXP |
Nevirapine results in increased expression of MEOX2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 6:53,856,760...53,917,467
Ensembl chr 6:53,856,758...53,917,467
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
Nevirapine results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Mfsd2a |
MFSD2 lysolipid transporter A, lysophospholipid |
increases expression |
ISO |
Nevirapine results in increased expression of MFSD2A mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
|
|
G |
Mgp |
matrix Gla protein |
increases expression |
EXP |
Nevirapine results in increased expression of MGP mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of MRC1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Ms4a7 |
membrane spanning 4-domains A7 |
decreases expression |
EXP |
Nevirapine results in decreased expression of MS4A7 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:207,969,117...207,984,743
Ensembl chr 1:207,968,761...207,983,260
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of NAMPT mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ndufaf4 |
NADH:ubiquinone oxidoreductase complex assembly factor 4 |
increases expression |
EXP |
Nevirapine results in increased expression of NDUFAF4 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:38,605,169...38,610,341
Ensembl chr 5:38,605,153...38,610,336
|
|
G |
Nlrc5 |
NLR family, CARD domain containing 5 |
increases expression |
ISO |
Nevirapine results in increased expression of NLRC5 |
CTD |
PMID:26626330 |
|
NCBI chr19:10,477,638...10,581,023
Ensembl chr19:10,477,628...10,562,121
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of NPAS2 mRNA; Nevirapine results in decreased expression of NPAS2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
|
|
G |
Nptx2 |
neuronal pentraxin 2 |
increases expression |
EXP |
Nevirapine results in increased expression of NPTX2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of NR1D1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Nevirapine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; [Nevirapine results in increased activity of NR1I3 protein] which results in increased expression of CYP2B6 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrep |
neuronal regeneration related protein |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of NREP mRNA; Nevirapine results in decreased expression of NREP mRNA |
CTD |
PMID:23947594 |
|
NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
decreases expression |
ISO |
Nevirapine results in decreased expression of OSGIN1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
decreases expression |
EXP |
Nevirapine results in decreased expression of P2RX7 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Pcp4l1 |
Purkinje cell protein 4-like 1 |
decreases expression |
EXP |
Nevirapine results in decreased expression of PCP4L1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:83,588,992...83,612,631
Ensembl chr13:83,588,992...83,609,966
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of PDK4 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Nevirapine results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
increases expression |
EXP |
Nevirapine results in increased expression of PIK3IP1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr14:78,204,668...78,216,616
Ensembl chr14:78,204,053...78,216,608
|
|
G |
Pim3 |
Pim-3 proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Nevirapine results in increased expression of PIM3 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 7:119,953,377...119,956,587
Ensembl chr 7:119,953,175...119,956,587
|
|
G |
Pir |
pirin |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of PIR mRNA |
CTD |
PMID:23947594 |
|
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
|
|
G |
Pira2 |
paired-Ig-like receptor A2 |
decreases expression |
EXP |
Nevirapine results in decreased expression of PIRA2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:65,352,125...65,422,842
Ensembl chr 1:65,415,946...65,422,853
|
|
G |
Pla2g12a |
phospholipase A2, group XIIA |
increases expression |
ISO |
Nevirapine results in increased expression of PLA2G12A mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 2:218,436,497...218,452,742
Ensembl chr 2:218,436,513...218,452,740
|
|
G |
Plin4 |
perilipin 4 |
increases expression |
ISO |
Nevirapine results in increased expression of PLIN4 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 9:929,168...938,062
Ensembl chr 9:929,176...938,056
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of PNPLA2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
EXP ISO |
Nevirapine metabolite results in increased expression of POR mRNA; Nevirapine results in increased expression of POR mRNA |
CTD |
PMID:23947594 PMID:38636494 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Nevirapine results in increased expression of PPARG mRNA |
CTD |
PMID:21619898 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of PPP2R2B mRNA; Nevirapine results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:23947594 |
|
NCBI chr18:34,653,716...35,080,889
Ensembl chr18:34,653,721...35,081,025
|
|
G |
Prf1 |
perforin 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of PRF1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Pycr1 |
pyrroline-5-carboxylate reductase 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of PYCR1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr10:105,917,732...105,922,658
Ensembl chr10:105,917,680...105,922,549
|
|
G |
Rapgef4 |
Rap guanine nucleotide exchange factor 4 |
increases expression |
ISO |
Nevirapine results in increased expression of RAPGEF4 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 3:56,809,388...57,101,332
Ensembl chr 3:56,809,270...57,102,316
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
increases expression |
ISO |
Nevirapine results in increased expression of RASD1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186
|
|
G |
Rbm3 |
RNA binding motif protein 3 |
increases expression |
EXP |
Nevirapine results in increased expression of RBM3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr X:14,348,909...14,352,387
Ensembl chr X:14,348,910...14,353,580
|
|
G |
Retreg1 |
reticulophagy regulator 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of RETREG1 mRNA; Nevirapine results in increased expression of RETREG1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:76,335,609...76,474,817
Ensembl chr 2:76,335,609...76,493,898
|
|
G |
RGD1359108 |
similar to RIKEN cDNA 3110043O21 |
increases expression |
ISO |
Nevirapine results in increased expression of C9ORF72 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 5:49,766,340...49,791,434
Ensembl chr 5:49,766,325...49,791,408
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
increases expression |
ISO |
Nevirapine results in increased expression of RGS16 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857
|
|
G |
Rhbdd2 |
rhomboid domain containing 2 |
increases expression |
EXP |
Nevirapine results in increased expression of RHBDD2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr12:21,043,605...21,054,305
Ensembl chr12:21,043,608...21,054,289
|
|
G |
Rhobtb1 |
Rho-related BTB domain containing 1 |
increases expression |
ISO |
Nevirapine results in increased expression of RHOBTB1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr20:19,327,142...19,456,121
Ensembl chr20:19,327,155...19,403,012
|
|
G |
Rprm |
reprimo, TP53 dependent G2 arrest mediator homolog |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of RPRM mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 3:38,539,581...38,540,998
Ensembl chr 3:38,539,581...38,540,998
|
|
G |
S100a7a |
S100 calcium binding protein A7A |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of S100A7A mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:176,151,405...176,155,846
Ensembl chr 2:176,151,288...176,156,441
|
|
G |
Scp2 |
sterol carrier protein 2 |
increases expression |
ISO |
Nevirapine results in increased expression of SCP2 |
CTD |
PMID:26626330 |
|
NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression |
ISO |
Nevirapine results in increased expression of SGK1 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Slamf9 |
SLAM family member 9 |
decreases expression |
EXP |
Nevirapine results in decreased expression of SLAMF9 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr13:84,941,896...84,944,749
Ensembl chr13:84,941,982...84,944,748
|
|
G |
Slc25a51 |
solute carrier family 25, member 51 |
increases expression |
ISO |
Nevirapine results in increased expression of SLC25A51 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 5:59,649,980...59,663,454
Ensembl chr 5:59,649,744...59,663,581
|
|
G |
Slc34a2 |
solute carrier family 34 member 2 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of SLC34A2 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
increases expression |
ISO |
Nevirapine results in increased expression of SLC38A2 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
[Nevirapine co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [Nevirapine co-treated with TSHB protein] results in increased expression of SLC5A5 protein |
CTD |
PMID:16030158 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Nevirapine results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression decreases expression |
ISO EXP |
Nevirapine results in increased expression of SREBF1 mRNA Nevirapine metabolite results in decreased expression of SREBF1 mRNA |
CTD |
PMID:21619898 PMID:23947594 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases activity |
EXP |
Nevirapine metabolite results in increased activity of SULT1A1 protein; Nevirapine results in increased activity of SULT1A1 protein |
CTD |
PMID:27417440 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Tat |
tyrosine aminotransferase |
increases expression |
ISO |
Nevirapine results in increased expression of TAT mRNA |
CTD |
PMID:38636494 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Tg |
thyroglobulin |
increases expression |
ISO |
Nevirapine results in increased expression of TG mRNA; Nevirapine results in increased expression of TG protein |
CTD |
PMID:16030158 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
increases expression |
ISO |
Nevirapine results in increased expression of TGFB3 mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Tmem64 |
transmembrane protein 64 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of TMEM64 mRNA; Nevirapine results in increased expression of TMEM64 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:28,698,947...28,745,384
Ensembl chr 5:28,698,918...28,745,330
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
Nevirapine results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
increases expression |
ISO |
Nevirapine results in increased expression of TNFRSF1B mRNA |
CTD |
PMID:38636494 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tox3 |
TOX high mobility group box family member 3 |
increases expression |
EXP |
Nevirapine results in increased expression of TOX3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr19:16,648,338...16,757,151
Ensembl chr19:16,648,342...16,757,148
|
|
G |
Tpo |
thyroid peroxidase |
increases expression |
ISO |
Nevirapine results in increased expression of TPO mRNA; Nevirapine results in increased expression of TPO protein |
CTD |
PMID:16030158 |
|
NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Trim24 |
tripartite motif-containing 24 |
decreases expression |
EXP |
Nevirapine results in decreased expression of TRIM24 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 4:66,567,342...66,692,029
Ensembl chr 4:66,566,686...66,717,241
|
|
G |
Trim63 |
tripartite motif containing 63 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of TRIM63 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
increases expression |
EXP |
Nevirapine results in increased expression of TSC22D3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[Nevirapine co-treated with TSHB protein] results in increased expression of SLC5A5 mRNA; [Nevirapine co-treated with TSHB protein] results in increased expression of SLC5A5 protein; Nevirapine promotes the reaction [TSHB protein affects the abundance of Iodine]; sodium perchlorate inhibits the reaction [Nevirapine promotes the reaction [TSHB protein affects the abundance of Iodine]] |
CTD |
PMID:16030158 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
increases expression |
ISO |
Nevirapine results in increased expression of TSHR mRNA |
CTD |
PMID:16030158 |
|
NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Tsku |
tsukushi, small leucine rich proteoglycan |
increases expression |
EXP |
Nevirapine results in increased expression of TSKU mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:152,660,259...152,671,682
Ensembl chr 1:152,656,693...152,672,588
|
|
G |
Ucp1 |
uncoupling protein 1 |
increases expression |
ISO |
Nevirapine results in increased expression of UCP1 |
CTD |
PMID:16038477 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ucp3 |
uncoupling protein 3 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of UCP3 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression |
EXP |
Nevirapine metabolite results in increased expression of VCAM1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Nevirapine results in decreased expression of VEGFA mRNA |
CTD |
PMID:19152342 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vsnl1 |
visinin-like 1 |
decreases expression |
EXP |
Nevirapine metabolite results in decreased expression of VSNL1 mRNA; Nevirapine results in decreased expression of VSNL1 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 6:34,038,641...34,159,479
Ensembl chr 6:34,038,642...34,159,479
|
|
G |
Zap70 |
zeta chain of T cell receptor associated protein kinase 70 |
increases expression |
EXP |
Nevirapine results in increased expression of ZAP70 mRNA |
CTD |
PMID:23947594 |
|
NCBI chr 9:38,989,750...39,011,701
Ensembl chr 9:38,989,750...39,011,700
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Phosphates results in decreased expression of AKT1 mRNA] |
CTD |
PMID:23308213 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Dmp1 |
dentin matrix acidic phosphoprotein 1 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Phosphates results in increased expression of DMP1 mRNA] |
CTD |
PMID:20185895 |
|
NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323
|
|
G |
Phex |
phosphate regulating endopeptidase X-linked |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [beta-glycerophosphoric acid results in increased expression of PHEX mRNA] |
CTD |
PMID:18500657 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions increases import |
EXP |
Foscarnet inhibits the reaction [SLC16A1 protein results in increased transport of Benzoic Acid] SLC16A1 protein results in increased import of Foscarnet |
CTD |
PMID:10579682 PMID:10714609 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc20a1 |
solute carrier family 20 member 1 |
decreases activity multiple interactions increases expression |
ISO EXP |
Foscarnet results in decreased activity of SLC20A1 protein Foscarnet inhibits the reaction [Phosphates results in increased expression of SLC20A1 mRNA] Foscarnet results in increased expression of SLC20A1 mRNA |
CTD |
PMID:15641067 PMID:17438129 PMID:23308213 |
|
NCBI chr 3:116,427,095...116,441,049
Ensembl chr 3:116,427,098...116,441,051
|
|
G |
Slc20a2 |
solute carrier family 20 member 2 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Phosphates results in increased expression of SLC20A2 mRNA] |
CTD |
PMID:23308213 |
|
NCBI chr16:69,460,850...69,551,418
Ensembl chr16:69,460,462...69,521,711
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Calcium results in increased expression of SLC23A2 mRNA]; Foscarnet inhibits the reaction [Phosphates results in increased expression of SLC23A2 mRNA] |
CTD |
PMID:12788230 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
Foscarnet inhibits the reaction [Calcium results in increased expression of SPP1 mRNA]; Foscarnet inhibits the reaction [Phosphates results in increased expression of SPP1 mRNA]; Foscarnet inhibits the reaction [Phosphates results in increased expression of SPP1 protein] |
CTD |
PMID:12788230 PMID:17383965 PMID:18412142 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stc1 |
stanniocalcin 1 |
increases expression |
EXP |
Foscarnet results in increased expression of STC1 mRNA |
CTD |
PMID:17438129 |
|
NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Tenofovir results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
affects expression |
ISO |
Tenofovir affects the expression of ACACB mRNA |
CTD |
PMID:20032539 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Tenofovir results in increased expression of BNIP3L protein |
CTD |
PMID:23640862 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein; Melatonin inhibits the reaction [Tenofovir results in increased expression of and results in increased activity of CASP3 protein]; Tenofovir results in increased expression of and results in increased activity of CASP3 protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of CASP3 protein] Tenofovir results in increased expression of CASP3 mRNA |
CTD |
PMID:33146023 PMID:36309141 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
EXP |
Melatonin inhibits the reaction [Tenofovir results in increased expression of CASP9 protein] |
CTD |
PMID:33146023 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in decreased activity of CAT protein |
CTD |
PMID:34118364 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression multiple interactions |
ISO |
Tenofovir results in increased expression of CCL20 mRNA Tenofovir results in increased expression of and results in increased secretion of CCL20 protein |
CTD |
PMID:24205323 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of CDKN1A protein Tenofovir results in increased expression of CDKN1A protein |
CTD |
PMID:31545371 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Tenofovir results in decreased activity of CYP2E1 protein |
CTD |
PMID:17162464 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Ddx3y |
DEAD box helicase 3, Y-linked |
increases expression |
EXP |
Tenofovir results in increased expression of DDX3Y mRNA |
CTD |
PMID:37852574 |
|
NCBI chr Y:1,115,095...1,135,754
Ensembl chr Y:1,116,309...1,135,706
|
|
G |
Edn1 |
endothelin 1 |
increases secretion multiple interactions |
ISO |
Tenofovir results in increased secretion of EDN1 protein coenzyme Q10 inhibits the reaction [Tenofovir results in increased secretion of EDN1 protein] |
CTD |
PMID:23640862 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
affects phosphorylation |
ISO |
Tenofovir affects the phosphorylation of EIF2S1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Fgb |
fibrinogen beta chain |
decreases expression |
EXP |
Tenofovir results in decreased expression of FGB mRNA |
CTD |
PMID:37852574 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Gjc2 |
gap junction protein, gamma 2 |
increases expression |
EXP |
Tenofovir results in increased expression of GJC2 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr10:43,962,642...43,971,358
Ensembl chr10:43,962,642...43,970,467
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
increases secretion multiple interactions |
ISO |
Tenofovir results in increased secretion of HAVCR1 protein Tenofovir inhibits the reaction [cidofovir results in increased secretion of HAVCR1 protein] |
CTD |
PMID:29738843 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions |
EXP |
Tenofovir results in decreased expression of HMOX1 protein Melatonin inhibits the reaction [Tenofovir results in decreased expression of HMOX1 protein] |
CTD |
PMID:33146023 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
affects expression |
ISO |
Tenofovir affects the expression of HSD11B1 mRNA |
CTD |
PMID:20032539 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
affects expression |
ISO |
Tenofovir affects the expression of HSPD1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of IL1B protein] |
CTD |
PMID:36309141 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
EXP |
Tenofovir results in decreased expression of IRF4 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Kdm5d |
lysine demethylase 5D |
increases expression |
EXP |
Tenofovir results in increased expression of KDM5D mRNA |
CTD |
PMID:37852574 |
|
NCBI chr Y:527,069...624,019
Ensembl chr Y:530,401...624,018
|
|
G |
Klf15 |
KLF transcription factor 15 |
decreases expression |
EXP |
Tenofovir results in decreased expression of KLF15 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr 4:122,965,718...122,978,403
Ensembl chr 4:122,965,807...122,978,374
|
|
G |
Lipe |
lipase E, hormone sensitive type |
affects expression |
ISO |
Tenofovir affects the expression of LIPE mRNA |
CTD |
PMID:20032539 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
affects expression |
ISO |
Tenofovir affects the expression of LONP1 protein |
CTD |
PMID:27041070 |
|
NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771
|
|
G |
Lpin1 |
lipin 1 |
decreases expression |
EXP |
Tenofovir results in decreased expression of LPIN1 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
affects phosphorylation |
ISO |
Tenofovir affects the phosphorylation of MAPK8 protein |
CTD |
PMID:27041070 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased activity of MPO protein |
CTD |
PMID:34118364 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
multiple interactions |
ISO |
Tenofovir promotes the reaction [Didanosine results in decreased expression of COX2 mRNA] |
CTD |
PMID:16940060 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
EXP |
Tenofovir results in decreased expression of NFKBIA protein |
CTD |
PMID:27899301 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
Tenofovir results in increased expression of NOS2 mRNA; Tenofovir results in increased expression of NOS2 protein Melatonin inhibits the reaction [Tenofovir results in increased expression of NOS2 protein] |
CTD |
PMID:27899301 PMID:33146023 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions decreases phosphorylation |
ISO |
coenzyme Q10 inhibits the reaction [Tenofovir results in decreased phosphorylation of NOS3 protein] |
CTD |
PMID:23640862 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects expression |
ISO |
Tenofovir affects the expression of NR3C1 mRNA |
CTD |
PMID:20032539 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression |
ISO |
Tenofovir results in increased expression of NT5E mRNA |
CTD |
PMID:24205323 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nt5m |
5',3'-nucleotidase, mitochondrial |
decreases expression |
ISO |
Tenofovir results in decreased expression of NT5M mRNA |
CTD |
PMID:24205323 |
|
NCBI chr10:44,652,845...44,680,549
Ensembl chr10:44,652,975...44,679,150
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases expression multiple interactions |
EXP |
Tenofovir results in increased expression of PARP1 protein Melatonin inhibits the reaction [Tenofovir results in increased expression of PARP1 protein] |
CTD |
PMID:33146023 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression |
ISO |
Tenofovir affects the expression of PPARG mRNA |
CTD |
PMID:20032539 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[Emtricitabine co-treated with Tenofovir] results in decreased expression of PRKN protein |
CTD |
PMID:31545371 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Tenofovir results in increased expression of PTGS2 mRNA; Tenofovir results in increased expression of PTGS2 protein |
CTD |
PMID:27899301 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression affects localization |
EXP |
Melatonin inhibits the reaction [Tenofovir affects the localization of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of and results in increased activity of RELA protein]; Melatonin inhibits the reaction [Tenofovir results in increased expression of RELA mRNA]; Tenofovir results in increased expression of and results in increased activity of RELA protein |
CTD |
PMID:27899301 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt3 |
sirtuin 3 |
increases expression |
ISO |
Tenofovir results in increased expression of SIRT3 protein |
CTD |
PMID:27041070 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
increases response to substance multiple interactions increases import |
ISO |
SLC22A6 protein results in increased susceptibility to Tenofovir Probenecid inhibits the reaction [SLC22A6 protein results in increased susceptibility to Tenofovir]; SLC22A6 protein results in increased uptake of and results in increased susceptibility to Tenofovir; Tenofovir inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] SLC22A6 protein results in increased import of Tenofovir |
CTD |
PMID:23856525 PMID:25448811 PMID:29738843 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases response to substance increases import |
ISO |
SLC22A8 protein results in increased susceptibility to Tenofovir SLC22A8 protein results in increased import of Tenofovir |
CTD |
PMID:25448811 PMID:29738843 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases expression multiple interactions |
ISO EXP |
Tenofovir results in decreased expression of TNF mRNA Tenofovir results in increased expression of TNF mRNA; Tenofovir results in increased expression of TNF protein [efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein; Zinc inhibits the reaction [[efavirenz co-treated with Lamivudine co-treated with Tenofovir] results in increased expression of TNF protein] |
CTD |
PMID:24205323 PMID:27899301 PMID:36309141 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
[Emtricitabine co-treated with Tenofovir] results in increased expression of TP53 protein Tenofovir results in increased expression of TP53 protein |
CTD |
PMID:31545371 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Usp18 |
ubiquitin specific peptidase 18 |
increases expression |
EXP |
Tenofovir results in increased expression of USP18 mRNA |
CTD |
PMID:37852574 |
|
NCBI chr 4:154,471,634...154,499,154
Ensembl chr 4:154,471,592...154,499,144
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
EXP |
Zalcitabine affects the phosphorylation of AKT1 protein |
CTD |
PMID:19781600 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Zalcitabine binds to ALB protein |
CTD |
PMID:15814459 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ano3 |
anoctamin 3 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of ANO3 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance |
ISO |
APEX1 protein mutant form results in increased susceptibility to Zalcitabine |
CTD |
PMID:17259346 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of ARNT2 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of ATP2B4 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of BPTF mRNA |
CTD |
PMID:18606552 |
|
NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769
|
|
G |
C10h17orf75 |
similar to human chromosome 17 open reading frame 75 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of C10H17ORF75 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr10:65,360,924...65,373,864
Ensembl chr10:65,360,924...65,373,864
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Zalcitabine results in increased expression of CCL2 protein |
CTD |
PMID:17761732 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
EXP |
Zalcitabine results in increased expression of CXCL12 mRNA |
CTD |
PMID:17292584 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
EXP |
Zalcitabine results in increased expression of CXCR4 mRNA |
CTD |
PMID:17292584 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Dck |
deoxycytidine kinase |
affects response to substance |
ISO |
DCK protein affects the susceptibility to Zalcitabine |
CTD |
PMID:11952160 |
|
NCBI chr14:19,305,218...19,326,247
Ensembl chr14:19,305,218...19,326,247
|
|
G |
Depdc1b |
DEP domain containing 1B |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of DEPDC1B mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Dlg5 |
discs large MAGUK scaffold protein 5 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of DLG5 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr15:75,786...209,735
Ensembl chr15:75,786...187,837
|
|
G |
Esrrg |
estrogen-related receptor gamma |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of ESRRG mRNA |
CTD |
PMID:18606552 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fam81a |
family with sequence similarity 81, member A |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of FAM81A mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 8:70,762,852...70,821,898
Ensembl chr 8:70,763,614...70,821,875
|
|
G |
Fpgt |
fucose-1-phosphate guanylyltransferase |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of FPGT mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:244,099,076...244,119,899
|
|
G |
Gla |
galactosidase, alpha |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of GLA mRNA |
CTD |
PMID:18606552 |
|
NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
increases response to substance increases expression multiple interactions |
ISO EXP |
HTR2A gene results in increased susceptibility to Zalcitabine Zalcitabine results in increased expression of HTR2A protein [alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol binds to and results in decreased activity of HTR2A protein] which results in decreased susceptibility to Zalcitabine |
CTD |
PMID:17888573 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression multiple interactions |
ISO |
Zalcitabine results in decreased expression of IL2RA mRNA; Zalcitabine results in decreased expression of IL2RA protein Zidovudine promotes the reaction [Zalcitabine results in decreased expression of IL2RA mRNA]; Zidovudine promotes the reaction [Zalcitabine results in decreased expression of IL2RA protein] |
CTD |
PMID:7606800 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Irf7 |
interferon regulatory factor 7 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of IRF7 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of KIF5A mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858
|
|
G |
Lama5 |
laminin subunit alpha 5 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of LAMA5 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451
|
|
G |
Luzp2 |
leucine zipper protein 2 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of LUZP2 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 1:105,597,291...105,983,605
Ensembl chr 1:105,597,307...105,981,183
|
|
G |
Midn |
midnolin |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of MIDN mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 7:9,548,100...9,559,605
Ensembl chr 7:9,549,650...9,559,752
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
decreases expression multiple interactions |
ISO |
Zalcitabine results in decreased expression of COX1 protein Uridine inhibits the reaction [Zalcitabine results in decreased expression of COX1 protein] |
CTD |
PMID:17187420 PMID:18823003 PMID:20032772 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt-co2 |
mitochondrially encoded cytochrome c oxidase II |
decreases expression |
EXP |
Zalcitabine results in decreased expression of COX2 mRNA |
CTD |
PMID:19781600 |
|
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
|
|
G |
Mt-co3 |
mitochondrially encoded cytochrome c oxidase III |
decreases expression |
ISO |
Zalcitabine results in decreased expression of COX3 protein |
CTD |
PMID:17508937 |
|
NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
|
|
G |
Ndufb11 |
NADH:ubiquinone oxidoreductase subunit B11 |
multiple interactions |
ISO |
Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein] |
CTD |
PMID:17904600 |
|
NCBI chr X:1,572,805...1,575,063
Ensembl chr X:1,572,785...1,575,062
|
|
G |
Necab1 |
N-terminal EF-hand calcium binding protein 1 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of NECAB1 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 5:28,357,859...28,578,642
Ensembl chr 5:28,357,859...28,578,642 Ensembl chr 5:28,357,859...28,578,642
|
|
G |
Nkiras1 |
NFKB inhibitor interacting Ras-like 1 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of NKIRAS1 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr15:7,493,531...7,503,758
Ensembl chr15:7,493,531...7,503,854
|
|
G |
Notch1 |
notch receptor 1 |
increases mutagenesis |
ISO |
Zalcitabine results in increased mutagenesis of NOTCH1 gene |
CTD |
PMID:18798262 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Npy |
neuropeptide Y |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of NPY mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of NTRK2 mRNA alternative form |
CTD |
PMID:18606552 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Per2 |
period circadian regulator 2 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of PER2 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
|
|
G |
Rab27b |
RAB27B, member RAS oncogene family |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of RAB27B mRNA |
CTD |
PMID:18606552 |
|
NCBI chr18:63,597,554...63,794,124
Ensembl chr18:63,600,937...63,757,180
|
|
G |
Reg3b |
regenerating family member 3 beta |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of REG3B mRNA; [gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of REG3B protein |
CTD |
PMID:18606552 |
|
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
Robo2 |
roundabout guidance receptor 2 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of ROBO2 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr11:12,528,949...14,096,726
Ensembl chr11:12,528,951...13,041,536
|
|
G |
Sanbr |
SANT and BTB domain regulator of CSR |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of SANBR mRNA |
CTD |
PMID:18606552 |
|
NCBI chr14:97,516,652...97,585,955
Ensembl chr14:97,516,413...97,581,346
|
|
G |
Scube1 |
signal peptide, CUB domain and EGF like domain containing 1 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of SCUBE1 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 7:114,759,016...114,880,995
Ensembl chr 7:114,759,010...114,880,940
|
|
G |
Senp5 |
SUMO specific peptidase 5 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of SENP5 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr11:68,784,699...68,819,569
Ensembl chr11:68,784,957...68,819,562
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
multiple interactions increases uptake |
EXP |
Zalcitabine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine]; Zalcitabine promotes the reaction [SLC28A1 protein results in increased export of Uridine] SLC28A1 protein results in increased uptake of Zalcitabine |
CTD |
PMID:8027026 PMID:8700147 PMID:8713072 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
G |
Slc29a3 |
solute carrier family 29 member 3 |
affects transport |
ISO |
SLC29A3 protein affects the transport of Zalcitabine |
CTD |
PMID:19164483 |
|
NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388
|
|
G |
Slc35g2 |
solute carrier family 35, member G2 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of SLC35G2 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 8:101,085,579...101,113,339
Ensembl chr 8:101,085,545...101,113,349
|
|
G |
Slc4a8 |
solute carrier family 4 member 8 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in increased expression of SLC4A8 mRNA |
CTD |
PMID:18606552 |
|
NCBI chr 7:131,861,284...131,939,295
Ensembl chr 7:131,864,102...131,931,051
|
|
G |
St8sia3 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 |
multiple interactions |
EXP |
[gp120 protein, Human immunodeficiency virus 1 co-treated with Zalcitabine] results in decreased expression of ST8SIA3 mRNA |
CTD |
PMID:18606552 | |